HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Sunil Singhal Larry R. Kaiser Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kruklitis, R. J. Articles by Albelda, S. M. Search for Related Content PubMed PubMed Citation Articles by Kruklitis, R. J. Articles by Albelda, S. M. Related Collections Lung - other

J Thorac Cardiovasc Surg 2004;127:123-130
© 2004 The American Association for Thoracic Surgery

General thoracic surgery

Immuno-gene therapy with interferon-ß before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma

^a Pulmonary, Allergy, and Critical Care Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa, USA
^b Section of Thoracic Surgery, Division of Cardiothoracic Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pa, USA

Read at the Eighty-third Annual Meeting of The American Association for Thoracic Surgery, Boston, Mass, May 4-7, 2003.

Received for publication May 2, 2003; revisions received July 30, 2003; accepted for publication August 11, 2003.

^* Address for reprints: Dr Steven M. Albelda, Department of Pulmonary Medicine, 857 BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104, USA
albelda{at}mail.med.upenn.edu

OBJECTIVES: Immuno-gene therapy of mesothelioma with an adenovirus encoding interferon-ß mediated strong antitumor responses in murine models with low but not high tumor burden. Our goals were to determine the mechanisms responsible for this loss of efficacy and to test the hypothesis that the combination of preoperative adenovirus encoding interferon-ß and surgical resection would be effective in treating bulky tumors.

METHODS: Flank tumors of a mouse mesothelioma cell line were treated with adenovirus encoding interferon-ß or adenoviral vector encoding the bacterial protein ß-galactosidase. Cytotoxic T lymphocytes and tumor infiltration by T lymphocytes were measured. Tumors were surgically excised 72 hours later and tumor cells were injected in the contralateral flank to create a model of a metastatic focus. Tumor-free survival and distant metastatic disease were assessed.

RESULTS: Immuno-gene therapy effectively treated small tumors (<200 mm³) but did not reduce the size of large (>800 mm³) flank tumors. Although treatment with adenovirus encoding interferon-ß resulted in the generation of tumor-neutralizing splenocytes in large tumors, the number of T cells visualized within the tumors was minimal. Tumors treated with adenovirus encoding interferon-ß (versus adenoviral vector encoding the bacterial protein ß-galactosidase or phosphate-buffered saline solution) prior to debulking increased long-term tumor-free survival and resulted in two- to sixfold smaller foci of implanted tumor cells at 2 weeks postoperatively.

CONCLUSIONS: The use of adenovirus encoding interferon-ß or surgical debulking alone is ineffective in treating large tumors, but combining preoperative adenovirus encoding interferon-ß and surgical debulking significantly reduces tumor recurrence and improves long-term tumor-free survival. We postulate that adenovirus encoding interferon-ß amplifies the cytotoxic T-lymphocyte antitumor response, allowing elimination of residual tumor cells.

This article has been cited by other articles:

				M. Lucchi, A. Chella, F. Melfi, P. Dini, M. Ambrogi, L. Fino, G. Fontanini, and A. Mussi A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 529 - 534. [Abstract] [Full Text] [PDF]

				V. W. Rusch Editorial comment: A phase II study of intrapleural immunochemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy, and long-term subcutaneous IL-2 in stage II-III malignant pleural mesothelioma Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 534 - 535. [Full Text] [PDF]

				E. Suzuki, S. Kim, H.-K. Cheung, M. J. Corbley, X. Zhang, L. Sun, F. Shan, J. Singh, W.-C. Lee, S. M. Albelda, et al. A Novel Small-Molecule Inhibitor of Transforming Growth Factor {beta} Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection Cancer Res., March 1, 2007; 67(5): 2351 - 2359. [Abstract] [Full Text] [PDF]

				E. P. Spugnini, I. Cardillo, A. Verdina, S. Crispi, S. Saviozzi, R. Calogero, A. Nebbioso, L. Altucci, G. Cortese, R. Galati, et al. Piroxicam and Cisplatin in a mouse model of peritoneal mesothelioma. Clin. Cancer Res., October 15, 2006; 12(20): 6133 - 6143. [Abstract] [Full Text] [PDF]